
Nuvation Bio Receives Approval from Japan's Ministry of Health, Labour and Welfare for IBTROZITM for Patients with ...
IBTROZI will be marketed in Japan by Nippon Kayaku Approval is based on the pivotal Phase 2 TRUST studies, demonstrating IBTROZI's high rates and durability of responses Primary companion diagnostic approved in parallel Nuvation Bio Inc. (NYSE: NUVB), …